Insys Therapeutics Inc (NASDAQ:INSY) reported that the firm is committed to take responsibility for inappropriate measures of some ex-employees and has invested considerable resources over the last many years to set an effective compliance plan and establish a culture of high ethical standards within the company. The company has associated with relevant authorities so that it can sort problems caused by inappropriate actions of former employees.
Insys reported that recent federal indictments of five New York doctors involve allegations linked to former employees. The company not only need to take responsibility for their former employees’ actions, but also bring in the best ways to showcase their desire to be a valued participant of the healthcare community. It is committed to focus on the actions of existing staff and bring in an organization culture of best standards. They want to run the business with an objective of offering best services in interest of patients. Moreover, they intend to bring a change by putting their capital in advancing new treatment options for grave unmet patient needs.
Insys consider their actions over the last many years, including their considerable investment in R&D programs, showcase their commitment to these priorities and the firm’s future Over the last year, the company has deployed a series of major changes that establishes the foundation for a fresh strategic direction for the firm as a pioneer in pharmaceutical CBDs and spray technologies.
This foundation was established around elevated capabilities and new leadership at all levels of the firm, which has enabled them to aggressively reposition and expand their product pipeline. Most importantly, this base establishes a strong commitment to improve the quality of life of patients. They plan to advance solution for different orphan diseases through their R&D programs. The investment in R&D will support the underway transformation of the firm.